Antitumor efficacy of combination chemotherapy with UFT and cyclophosphamide against human breast cancer xenografts in nude mice

Anticancer Research

Volumn 19, Issue 3 A, 1999, Pages 1791-1796

  Haga, Shunsuke ^a   Shimizu, Tadao ^a   Imamura, Hiroshi ^a   Watanabe, Osamu ^a   Kinoshita, Jun ^a   Fukushima, Masakazu ^b   Kajiwara, Tetsuro ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b TAIHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Breast cancer; Combination therapy; Cyclophosphamide (CPA); Ribonucleotide reductase; Thymidine phosphorylase; Thymidylate synthase; UFT

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DRUG METABOLIZING ENZYME; FLUOROURACIL; RIBONUCLEOTIDE REDUCTASE; TEGAFUR; UFT; URACIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME ACTIVITY; FEMALE; MAXIMUM PERMISSIBLE DOSE; MOUSE; NONHUMAN; NUDE MOUSE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CISPLATIN; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; PYRIMIDINES; RIBONUCLEOTIDE REDUCTASES; TEGAFUR; TRANSPLANTATION, HETEROLOGOUS; URACIL;

EID: 0032806661     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Fisher B: A commentary on the role of the surgeon in primary breast cancer. Breast Cancer Res Treat 1: 17-26, 1981.
2. Smalley RV, Carpenter J, Bartolucci A: A comparison of cyclophosphamide, Adriamycin, 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, predonisone (CMFVP) in patients with metastatic breast cancer. Southeastern Cancer Study Group project. Cancer 40: 625-632, 1977.
3. Brincker H, Rose C, van de Maase H: A randomized study of CAF + TAM (tamoxifen) versus CMF + TAM in metastatic breast cancer. Proc Am Soc Clin Oncol 3: 113, 1984.
4. Smalley RV, Lefante J, Bartolucci A: A comparison of cyclophosphamide, Adriamycin and 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine and predonisone (CMFVP) in patients with advanced breast cancer. Breast Cancer Res Treat 3: 209-220, 1983.
5. Lokich JJ, Ahlgren JD, Gullo JJ, Philips JA and Fryer JG: A prospective randomized comparison of continuous infusion 5-fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a mid-Atlantic oncology program study. J Clin Oncol 7: 425-432, 1989.
6. Hansen R, Quebbeman E, Beatty P, Ritch P, Anderson T, Jenkins D, Frick J and Ausman R: Continuous 5-fluorouracil infusion in refractory carcinoma of breast. Breast Cancer Treat 10: 145-149, 1987.
7. Huans S, Pazdur R, Singhakowinta A, Samal B and Vaitkevicius VR: Low-dose continuous infusion of 5-fluorouracil, evaluation in advanced breast carcinoma. Cancer 63: 419-422, 1989.
8. Fujii S, Ikenaka K, Fukushima M and Shirasaka T: Effect of uracil and its derivatives on antitumor activity of 5-fluorouracil and 1-(2-tetrahydrofuryl)-5- fluorouracil. Gann 69: 763-772, 1978.
9. Ohta K, Taguchi T and Kimura K: Report on nationwide pooled data and cohort investigation in UFT phase II study. Cancer Chemother Pharmacol 22: 333-338, 1988.
10. Tashiro H, Nomura Y and Ohsaki A: A double blind comparative study of tegafur (FT) and UFT (a combination of tegafur and uracil) in advanced breast cancer. Jpn J Clin Oncol 24: 212-217, 1994.
11. Hirata K, Sasaki K, Yamamitsu S and Shirasaka T: A comparison of 5-fluorouracil concentration of 5-fluorouracil drip infusion versus orally UFT in plasma of same patients. Jpn J Cancer Chemother 20: 1409-1411, 1993.
12. Namatame K, Sasaki E, Ko Y, Shimada K, Takahashi H, Nakano H, Midorikawa T, Makuuchi M, Kimura K and Kumada K: A double-blind comparison of FUra plasma concentration by oral (UFT) vs continuous intravenous infusion (5-FU). Jpn J Cancer Chemother 20: 2417-2419, 1993.
13. Spears CP, Shahinian AH and Moran RG: In vivo kinetics of thymidylate synthase inhibition in 5-fluorouracil-sensitive and -resistant murine colon adenocarcinomas. Cancer Res 42: 450-456, 1982.
14. Ikenaka K, Shirasaka T, Kitano S and Fujii S: Effect of uracil on metabolism of 5- fluorouracil in vitro. Jpn J Cancer Res 70: 353-359, 1979.
15. Shirasaka T, Shimamoto Y and Fukushima M: Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res 53: 4004-4009, 1993.
16. Maehara Y, Nakamura H, Nakane Y, Kawai K, Okamoto M, Nagayama S, Shirasaka T and Fujii S: Activities of various enzymes of pyrimidine nucleotide and DNA synthesis in normal and neoplastic human tissues. Jpn J Cancer Res 73: 289-298, 1982.
17. Kimura K, Suga S, Shimaji T, Kitamura M, Kubo K, Suzuoki Y and Isobe K: Clinical basis of chemotherapy for gastric cancer with uracil and 1-(2-tetrahydrofuryl)-5-fluorouracil, Jpn J Soc Gastroenterol 15: 324-329, 1980.
18. Wada H, Hitomi S and Teramatsu T: Adjuvant chemotherapy after complete resection in non-small-cell lung cancer. West Japan Study Group for Lung Cancer Surgery. J Clin Oncol 14: 1048-1054, 1996.
19. Pazdur R, Lassere Y, Rhodes V, Ajani, JA, Sugarman SM, Patt YZ, Jones DV, Markowitz AB, Abbruzzese JL, Bready B and Levin B: Phase II trial of uracil and tegafur plus leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma. J Clin Oncol 12: 2296-3200, 1994.
20. Rustum YM: Mechanism-based improvement in the therapeutic selectivity of 5-FU prodrug alone and under conditions of metabolic modulation. Oncology 54(Suppl 1): 7-11, 1997.
21. Nukatsuka M, Fujioka A, Saito H, Uchida J, Nakano K, Takeda S and Unemi N: Prolongation of survival period and improvement of cancer cachexia by long term administration of UFT. Cancer Lett 104: 197-203, 1996.
22. Kurebayashi J, Nukatsuka M, Fujioka A, Saito H, Takeda S, Unemi N, Fukumori H, Kurosumi M, Sonoo H and Dickson RB: Postsurgical administration of uracil and Tegafur inhibits progression of micrometastasis of human breast cancer cells in nude mice. Clin Cancer Res 3: 653-659, 1997.
23. Hartman KY and Heidelberger C: Studies on fluorinated pyrimidines: XIII. Inhibition of thymidylate synthase. J Biol Chem 236: 3006-3018, 1961
24. Santi DV and MacHenry CS: %-Fluoro-2'-deoxyuridylate: covalent complex with thymidylate synthase. Proc Natl Acad Sci USA 69: 1855-1857, 1972.
25. Weeler GP: Alkylating agents. In: Cancer medicine, edited by Holland JF and Frei III E. Lee and Febiger, Philadelphia, 1982.
26. Sawada N, Ishikawa T, Fukase Y, Nishida M, Yoshikubo T and Ishitsuka H: Induction of thymidine phosphorylase activity and enhancement of Capecitabine efficacy by Taxol/Taxotere in human cancer xenografts. Clin Cancer Res 4: 1013-1019, 1998.